Skip to main content
Arlyn

Access agent for life sciences

Arlyn builds the intelligence layer for access to life science innovation, transforming an opaque and fragmented drug access ecosystem into a comprehensive, machine-readable view so drug innovators can see barriers clearly and measure whether access investment drives real patient impact.

Veltraxa47 commercial plans150 payers

For illustration only.

Trusted by the world’s leading life sciences innovators.
How it works

We make the U.S. drug access ecosystem machine-readable.

Arlyn builds a structured, continuously updated map of the drug access ecosystem across tens of thousands of plans, employers, TPAs, PBMs, GPOs, formularies, policies, utilization management rules, site-of-care restrictions, benefit designs etc. Spanning millions of records, Arlyn tracks how these entities relate and evolve over time to make market access transparent, analyzable, and actionable.Arlyn connects market access reality to patient access solutions.
Case study

One access question, followed all the way through.

See our case study
+0.9%average GTN improvement

Questions Arlyn can answer

Illustrative.

Every drug-access decision should run through one intelligence layer.

Arlyn helps drug innovators move from fragmented analysis to a system that understands access reality, commercial commitments, and where action is required.